ReNeuron automates stem cell manufacturing process

8 April 2009

The UK's ReNeuron Group says a paper has been published in the journal Biotechnology Letters, demonstrating successful automation of the  manufacturing if its ReN001 neural stem cell line for stroke.

The research was conducted in collaboration with the remedi Project at  Loughborough University, UK. ReNeuron's standard cell manufacturing  process was adapted and transferred to an automated system using a  commercially-available robotic cell culture system - the CompacT SelecT  designed and manufactured by The Automation Partnership, an innovative  UK-based company focused on the development of advanced automated  systems for the global life sciences market. With minor modifications of  the standard process, the robot was programmed to successfully  manufacture a batch of cells. The growth rate and the quality  characteristics were identical to those produced manually.

John Sinden, chief scientific officer of ReNeuron, said: "the successful  automation of our ReN001 manufacturing process heralds two exciting  advances. Firstly, ReNeuron has access to a precise platform allowing  optimization of its cell culture process, leading to lower costs and  increased yield. Secondly, we anticipate that automation will deliver a  more reliable scale of manufacture progressing the therapy into later  stage trials and beyond."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight